game changer
Recently Published Documents


TOTAL DOCUMENTS

1172
(FIVE YEARS 630)

H-INDEX

28
(FIVE YEARS 8)

Author(s):  
Lydia Noh ◽  
Felix Pham ◽  
Lara Haddad ◽  
Theresa Burkhard ◽  
Laurie Paletz ◽  
...  

Abstract Purpose Tenecteplase is a thrombolytic that is more fibrin specific, has a longer half-life, and is easier to administer than alteplase for acute ischemic stroke (AIS). This article outlines the pharmacy experience and perspective on implementation of tenecteplase as the treatment of choice for AIS. Summary Tenecteplase has been of increasing interest for AIS and is currently being studied in several clinical trials. Although it is not indicated by the Food and Drug Administration for AIS, several published studies and an update to stroke guidelines from the American Heart Association and American Stroke Association support its use in this setting. In January 2021, Cedars-Sinai Health System made the decision to add tenecteplase to the formulary for AIS in addition to keeping alteplase for patients who met the criterion of being outside the 4.5-hour window following stroke onset. Along with the added benefits of having tenecteplase on formulary come challenges of managing multiple thrombolytics for the same indication. Identifying key stakeholders and creating an interdisciplinary team are critical to ensure safe transitions. Conclusion Institutions can safely transition from alteplase to tenecteplase as a thrombolytic of choice for AIS.


2022 ◽  
Author(s):  
Emre Yekedüz ◽  
Güngör Utkan ◽  
Yüksel Ürün

HIV-infected patients are more susceptible to cancer due to their immune-compromised condition and HIV infection. Chronic inflammation and immune dysregulation are the main causes of cancer development in these patients. Because of lymphopenia and an immune-compromised condition, most HIV-infected patients with cancer were not considered for cytotoxic therapies, such as chemotherapy and radiotherapy. Immune checkpoint inhibitors (ICIs) have become a game-changer in many cancer types. However, not enough prospective data is available regarding the use of ICIs in HIV-infected patients with cancer. Retrospective data from case reports/series showed that ICIs are safe in HIV-infected patients with cancer.


Cancers ◽  
2022 ◽  
Vol 14 (2) ◽  
pp. 315
Author(s):  
Niloy R. Datta ◽  
Bharati M. Jain ◽  
Zatin Mathi ◽  
Sneha Datta ◽  
Satyendra Johari ◽  
...  

Loco-regional hyperthermia at 40–44 °C is a multifaceted therapeutic modality with the distinct triple advantage of being a potent radiosensitizer, a chemosensitizer and an immunomodulator. Risk difference estimates from pairwise meta-analysis have shown that the local tumour control could be improved by 22.3% (p < 0.001), 22.1% (p < 0.001) and 25.5% (p < 0.001) in recurrent breast cancers, locally advanced cervix cancer (LACC) and locally advanced head and neck cancers, respectively by adding hyperthermia to radiotherapy over radiotherapy alone. Furthermore, thermochemoradiotherapy in LACC have shown to reduce the local failure rates by 10.1% (p = 0.03) and decrease deaths by 5.6% (95% CI: 0.6–11.8%) over chemoradiotherapy alone. As around one-third of the cancer cases in low-middle-income group countries belong to breast, cervix and head and neck regions, hyperthermia could be a potential game-changer and expected to augment the clinical outcomes of these patients in conjunction with radiotherapy and/or chemotherapy. Further, hyperthermia could also be a cost-effective therapeutic modality as the capital costs for setting up a hyperthermia facility is relatively low. Thus, the positive outcomes evident from various phase III randomized trials and meta-analysis with thermoradiotherapy or thermochemoradiotherapy justifies the integration of hyperthermia in the therapeutic armamentarium of clinical management of cancer, especially in low-middle-income group countries.


Livers ◽  
2022 ◽  
Vol 2 (1) ◽  
pp. 1-14
Author(s):  
Sheikh Mohammad Fazle Akbar ◽  
Mamun Al Mahtab ◽  
Osamu Yoshida ◽  
Yoichi Hiasa

Millions of people of the world suffer from chronic hepatitis B (CHB), a pathological entity in which the patients are chronically infected with hepatitis B virus (HBV) and express hepatitis B surface antigen (HBsAg) and HBV DNA, as well as evidence of liver damages. Considerable numbers of CHB patients develop cirrhosis of the liver and hepatocellular carcinoma if untreated. Two groups of drugs (interferons and nucleoside analogs) are used to treat CHB patients, but both are endowed with considerable adverse effects, increased costs, extended duration of therapy, and limited efficacy. Thus, there is a pressing need to develop new and innovative therapeutics for CHB patients, and many such drugs have been developed during the last four decades. Some of these drugs have inspired considerable optimism to be a game-changer for the treatment of CHB. Here, we first discuss why ongoing therapeutics such as interferon and nucleoside analogs could not stand the test of time. Next, we dissect the scope and limitation of evolving therapies for CHB by dissecting the cellular and molecular mechanisms of some of these innovative therapeutics.


2022 ◽  
Vol 18 (1) ◽  
pp. 16-17
Keyword(s):  

A look at a new way of monitoring water system compliance in the fight against legionella


2022 ◽  
pp. 162-171
Author(s):  
Chabi Gupta

As the COVID-19 pandemic continues to evolve even beyond a second wave, there is an urgent need for business organisations to rethink and reconfigure their strategies for long-term sustainability beyond the pandemic. Many organisations are already making changes in the way they run their businesses and the way they make decisions to emerge stronger. It can be observed that the pandemic has seriously affected the way business organisations are being operated. However, this research suggests during the discussion that what is required is a transformational change rather than a directed one for any business organisation. In the current scenario, AI is being seen as a key enabler for business organisations to be on the path to recovery. What the ‘modus operandi' beyond the pandemic will be is a relevant issue for businesses indicating further need of research in this area. Using financial analytics and AI in combination will bring in a transformational change that might be viewed as the ‘game changer' for businesses beyond the pandemic.


Sign in / Sign up

Export Citation Format

Share Document